No connection

Search Results

BCTXL

BEARISH
$1.25 Live
BriaCell Therapeutics Corp. · NASDAQ
$1.2 52W Range $1.32
Overview AI Snowflake Price Valuation Profitability Growth Health

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Jan 24, 2026
Market cap
N/A
P/E
N/A
ROE
-444.1%
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and financial distress. Despite a seemingly strong Current and Quick Ratio of 3.42, the company reports zero profitability across all margins and deeply negative ROE and ROA, signaling inefficient use of equity and assets. Valuation metrics are largely unavailable or non-existent, with no meaningful P/E, PEG, or EV/EBITDA data, while the stock shows no price momentum over multiple time horizons. The absence of Altman Z-Score and Graham Number, combined with stagnant performance and no analyst coverage, underscores extreme uncertainty and elevated risk.

Key Strengths

Current Ratio of 3.42 suggests short-term liquidity adequacy
Quick Ratio of 3.42 indicates ability to meet short-term obligations without inventory reliance
Price/Sales and EV/Revenue absence may imply limited revenue base rather than overvaluation
Insider Sentiment score of 40/100 shows some level of insider engagement
Stock price has remained stable near $1.25 with minimal volatility in recent periods

Key Risks

Piotroski F-Score of 2/9 indicates very weak financial health and high risk of underperformance
ROE of -444.07% and ROA of -161.64% reflect severe losses relative to equity and asset base
Zero gross, operating, and profit margins indicate no current path to profitability
No Altman Z-Score available, increasing uncertainty about bankruptcy risk
Lack of analyst coverage, target prices, and growth metrics signals low institutional interest and high information risk

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
20
Weak
Value
30
Future
20
Past
35
Health
15
Dividend
0
AI Verdict
High-risk speculative position with no fundamental support
Key drivers: Low Piotroski F-Score, Negative returns metrics, Absence of valuation and growth data, No analyst coverage
Confidence
80%
Value
30/100

Ref P/E, PEG, Graham Number

Positives
  • Price/Book ratio of 0.24 may suggest asset discount (if assets are realizable)
Watchpoints
  • No Graham Number or Intrinsic Value available
  • P/E and Forward P/E are N/A, indicating no earnings
  • No meaningful PEG or Price/Sales for comparison
Future
20/100

Ref Growth rates

Positives
No standout positives identified.
Watchpoints
  • Revenue and Earnings Growth (YoY and Q/Q) are all N/A
  • No Forward P/E or analyst growth estimates available
  • Technical Trend score of 0/100 indicates strong bearish momentum
Past
35/100

Ref Historical trends

Positives
  • 52-week range is narrow ($1.20–$1.32), suggesting price stability
Watchpoints
  • 5Y, 3Y, 1Y, 6M, 1M, and 1W price changes all at 0.0%
  • No historical trend indicating growth or recovery
Health
15/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Current and Quick Ratios above 3.0 indicate short-term liquidity
Watchpoints
  • Piotroski F-Score of 2/9 indicates poor financial health
  • ROE and ROA are deeply negative
  • No Altman Z-Score available for bankruptcy risk assessment
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • Dividend Strength is 0/100
  • No dividend yield, rate, or payout history

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.25

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for BCTXL and closest competitors.

Updated 2026-01-23
BCT
BriaCell Therapeutics Corp.
Primary
5Y
0.0%
3Y
0.0%
1Y
0.0%
6M
0.0%
1M
0.0%
1W
0.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
0.24
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
N/A
Market Cap
N/A

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin N/A
Gross Margin N/A
ROE -444.07%
ROA -161.64%

Growth

Revenue and earnings growth rates

Revenue Growth N/A
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
3.42
Strong
Quick Ratio
3.42
Excellent
Cash/Share
$5.4

Past News Coverage

Recent headlines mentioning BCTXL from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile